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Baseline Low-Density Lipoprotein
Cholesterol Is an Important Predictor
of the Benefit of Intensive Lipid-Lowering Therapy
A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and
Infection Therapy–Thrombolysis In Myocardial Infarction 22) Analysis
Roberto R. Giraldez, MD, Robert P. Giugliano, MD, SM, FACC, Satishkumar Mohanavelu, MS,
Sabina A. Murphy, MPH, Carolyn H. McCabe, BS, Christopher P. Cannon, MD, FACC,
Eugene Braunwald, MD, MACC
Boston, Massachusetts
Objectives This study sought to determine whether the benefit of intensive lipid-lowering therapy (LLT) is dependent on
baseline low-density lipoprotein cholesterol (LDL-C).
Background Aggressive LDL-C reduction with statins improves cardiovascular outcomes in acute and chronic coronary heart
disease (CHD). The importance of baseline LDL-C is unclear.
Methods We compared 2-year composites of death, myocardial infarction (MI), unstable angina, revascularization 30
days, and stroke (primary end point), and CHD death, MI, and revascularization 30 days (secondary end point)
in 2,986 statin-naïve patients with recent acute coronary syndrome (ACS) randomized to atorvastatin 80 mg ver-
sus pravastatin 40 mg in the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis In Myocardial Infarction 22) study stratified by quartiles of baseline LDL-C. Multivariable models
assessed whether the treatment benefit was dependent on baseline LDL-C.
Results A significant reduction in the hazards of the primary (hazard ratio [HR]: 0.63, 95% confidence interval [CI]: 0.47
to 0.85, p  0.002) and secondary (HR: 0.57, 95% CI: 0.42 to 0.79, p  0.001) end points occurred in patients
within the highest quartile (132 mg/dl) of baseline LDL-C treated with atorvastatin 80 mg. The benefit of in-
tensive therapy progressively declined as baseline LDL-C decreased. The lowest quartile (LDL-C 92 mg/dl) ex-
perienced similar rates of the primary (HR: 0.93, 95% CI: 0.69 to 1.25, p  0.63) and secondary (HR: 0.98, 95%
CI: 0.71 to 1.35, p  0.89) end points. Adjusted interaction tests between treatment and highest versus lowest
baseline LDL-C quartile were significant for the primary and secondary end points (p  0.03 and p  0.007, re-
spectively). Analyzing baseline LDL-C as a continuous variable, atorvastatin 80 mg was associated with improved
outcomes provided the baseline LDL-C was 66 mg/dl.
Conclusions A progressive reduction in the benefit of intensive LLT with atorvastatin 80 mg over pravastatin 40 mg occurred
in statin-naïve ACS patients as baseline LDL-C declined. (Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT–TIMI 22]; NCT00382460) (J Am Coll Cardiol
2008;52:914–20) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.046(
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mowering of low-density lipoprotein cholesterol (LDL-C)
ith statin therapy reduces the risk of death and cardiovas-
ular events in both primary and secondary prevention (1).
ontemporary trials have extended the findings of the initial
tudies by showing significant clinical benefit of intensive
ipid reduction to much lower LDL-C concentrations (2–4).
urrently, the National Cholesterol Education Program
rom the TIMI Study Group, Cardiovascular Division, Department of Medicine,
righam and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. The
ROVE IT–TIMI 22 trial was supported by a research grant from Bristol-Myers Squibb.p
Manuscript received April 4, 2008; revised manuscript received May 12, 2008,
ccepted May 12, 2008.NCEP) recommends an optional target LDL-C of 70
g/dl in patients at high risk of cardiovascular events (5,6).
See page 921
Despite the reduction in cardiovascular risk shown with
holesterol-lowering treatment, the PROVE IT–TIMI 22
Pravastatin or Atorvastatin Evaluation and Infection
herapy–Thrombolysis In Myocardial Infarction 22) trial as
ell as other analyses in patients with acute and chronic
oronary heart disease (CHD) have suggested that this benefit
ight be limited by baseline cholesterol values, indicating theresence of a threshold below which further LDL-C reduction
m
h
t
l
t
o
t
s
a
m
w
a
t
i
M
P
P
(
t
o
a
r
p
m
p
m
c
t
r
2
d
s
c
C
f
c
(
o
o
e
d
a
k
a
s
r
c
p
b
c
t
u
T
t
m
t
s
s
(
l
a
m
b
O
s
t
t
t
p
i
d
u
i
i
(
a
p
C
a
S
t
i
u
c
m
p
m
b
p
g
m
t
M
p
r
a
o
b
M
i
s
v
p
y
915JACC Vol. 52, No. 11, 2008 Giraldez et al.
September 9, 2008:914–20 Baseline LDL-C and Benefit of Lipid Loweringay not add clinical benefit (2,7,8). Other studies, however,
ave observed that similar magnitudes of LDL-C reduction
ranslated into fewer cardiovascular events regardless of base-
ine LDL-C (9–11). Therefore, controversy remains regarding
he influence of pre-treatment LDL-C on the clinical benefit
f lipid-lowering therapy.
The PROVE IT–TIMI 22 trial showed that intensive statin
reatment with atorvastatin 80 mg was associated with a
ignificant reduction in the composite rate of death or major
dverse cardiovascular events compared with a standard regi-
en with pravastatin 40 mg in high-risk patients admitted
ith acute coronary syndromes (ACS) followed up for an
verage of 24 months (2). This trial provided the opportunity
o evaluate the impact of baseline LDL-C on the benefit of
ntensive compared with standard lipid-lowering therapy.
ethods
atient population and study protocol. The design of the
ROVE IT–TIMI 22 trial has been reported previously
2,12). Briefly, men or women at least 18 years old hospi-
alized with ACS, either myocardial infarction (MI) (with
r without ST-segment elevation) or high-risk unstable
ngina, in the preceding 10 days were randomly assigned to
eceive pravastatin 40 mg or atorvastatin 80 mg daily. The
rotocol required the baseline total cholesterol to be 240
g/dl in statin-naïve patients or 200 mg/dl in patients on
rior statin therapy. Patients were managed with standard
edical and interventional treatment for ACS. Major ex-
lusion criteria included treatment with fibric acid deriva-
ives or niacin that could not be discontinued before
andomization, or creatinine 2.0 mg/dl.
Patients were followed up for 18 to 36 months (average
4 months) with visits and blood sample collection at 30
ays, 4 months, and every 4 months thereafter. Blood
amples were analyzed at a central laboratory. Total
holesterol, high-density lipoprotein cholesterol (HDL-
), and triglycerides were measured immediately on
reshly shipped plasma samples, using an enzymatic
olorimetric method and the Roche Modular system
LabCorp, Raritan, New Jersey), whereas LDL-C was
btained by calculation (Friedewald formula). The dose
f pravastatin was increased to 80 mg if the LDL-C level
xceeded 125 mg/dl on 2 consecutive measurements. The
ose of either study drug was halved in the event of
bnormal liver function test results, elevation of creatine
inase levels, or myalgias.
In the current analysis, patients who were not prescribed
statin before the qualifying admission (statin-naïve) were
tratified into quartiles of baseline LDL-C obtained at
andomization. These patients were selected as the primary
ohort of interest because the LDL-C at study entry in this
opulation would more accurately reflect the patients’ true
aseline level because it was not confounded by prior
hronic statin use. The LDL-C at 4 months was considered
o be the on-treatment value because it remained largely Snchanged throughout the study.
he data were analyzed in quar-
iles of baseline LDL-C to per-
it multivariate adjustment be-
ween subgroups of patients of
ufficient size. Results are pre-
ented as adjusted hazard ratios
HRs) between subgroups. Base-
ine LDL-C also was analyzed as
continuous variable to deter-
ine a threshold value for the
enefit of aggressive lipid therapy.
utcomes. The primary and
econdary outcomes measures in
his analysis were the same as for
he main PROVE IT–TIMI 22
rial (2,12). The primary end
oint was the time from random-
zation to the first occurrence of
eath from any cause, MI, doc-
mented unstable angina requir-
ng hospitalization, revascular-
zation with either percutaneous coronary intervention
PCI) or coronary artery bypass graft (CABG) performed
fter 30 days following randomization, and stroke. The
rincipal secondary outcome was a composite of death from
HD, nonfatal myocardial infarction, or revascularization
fter 30 days.
tatistical analysis. The comparison of baseline characteris-
ics and in-hospital treatment among statin-naïve patients
n the different quartiles of baseline LDL-C was performed
sing the Kruskal-Wallis test for continuous variables and
hi-square tests for categorical variables. A Cox regression
odel was used to evaluate the primary and secondary end
oints through follow-up (mean 2 years) in the pravastatin 40
g and atorvastatin 80 mg groups stratified by quartiles of
aseline LDL-C. We used Kaplan-Meier estimates to com-
are the primary and secondary outcomes between treatment
roups across LDL-C quartiles. Unadjusted and adjusted
odels were developed for assessment of an interaction be-
ween randomized therapy and quartiles of baseline LDL-C.
ultivariable analyses were performed for the prediction of the
rimary and secondary composite end points using the Cox
egression model and included variables of the baseline char-
cteristics significantly associated (p 0.05) with the outcome
f interest in the univariate analysis, treatment assignment,
aseline C-reactive protein, and quartiles of baseline LDL-C.
odel results are presented as HR with 95% confidence
ntervals (CIs). A p value0.05 was the threshold for nominal
ignificance for all comparisons.
The baseline LDL-C was also analyzed as a continuous
ariable using a locally weighted scatter plot smoother to
lot the primary end point using the Logit method. Anal-
ses were performed with Stata/SE version 9.2 (Stata
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass graft
CHD  coronary heart
disease
CI  confidence interval
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
NCEP  National
Cholesterol Education
Program
PCI  percutaneous
coronary interventiontatistical Software, StataCorp, College Station, Texas).
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Baseline LDL-C and Benefit of Lipid Lowering September 9, 2008:914–20esults
he analysis cohort included 2,986 statin-naïve patients
72% of the total 4,162 patients) enrolled in the PROVE
T–TIMI 22 trial. Of these, 1,488 patients were random-
zed to pravastatin 40 mg and 1,498 to atorvastatin 80 mg.
Baseline characteristics stratified by quartiles of baseline
DL-C are shown in Table 1. Patients with lower LDL-C
t presentation were older and had a higher prevalence of
ypertension and diabetes. In contrast, higher baseline
DL-C values were associated with a history of hyperlip-
demia. Despite differences in population characteristics and
isks across LDL-C quartiles, Killip class at presentation
nd rates of in-hospital PCI were similar.
rimary and secondary end points. The composite pri-
ary end point at 2 years occurred in 25.4% of the patients
n the pravastatin 40 mg group and 20.8% of the patients
andomized to atorvastatin 80 mg (HR: 0.80, 95% CI: 0.69
o 0.93, p  0.004). Similarly, the secondary end point
ccurred in 22.4% and 18.4% of the pravastatin 40 mg and
aseline Characteristics Stratified by Quartiles of LDL-C
Table 1 Baseline Characteristics Stratified by Quartiles of LDL-
All
(n  2,986)
Q
(n
Median baseline LDL-C, mg/dl 112
Range baseline LDL-C, mg/dl 31–275 
Baseline characteristics
Age (median), yrs 56
Male, % 78.2
White race,* % 90.5
Weight (median), kg 85.9
Hypertension, % 43.3
Hyperlipidemia, % 32.5
Current smoker, % 40.2
Diabetes mellitus, % 15.0
Peripheral arterial disease, % 3.8
Prior myocardial infarction, % 10.1
Prior PCI, % 7.7
Prior CABG, % 5.6
Congestive heart failure, % 2.0
Renal disease, % 8.8
Index presentation and prior medications
STEMI at admission, % 39.7
Killip class II,† % 4.9
Aspirin use in the previous 2 weeks, % 23.4
C-reactive protein (median), mg/dl 1.39
In-hospital treatment, %
Aspirin 94.4
Beta-blockers 85.9
Calcium-channel blockers 15.9
ACE inhibitors or ARBs 58.7
Statins between admission and randomization 47.5
PCI during index hospitalization 72.4
esults are expressed as percent of total patients with available information for the baseline char
resence of rales and/or jugular venous distension, class III as the presence of pulmonary edema
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary artery byp
TEMI  ST-segment elevation myocardial infarction.torvastatin 80 mg groups, respectively (HR: 0.80, 95% CI:
.68 to 0.94, p  0.007).
In the multivariable analysis, the use of atorvastatin 80
g was an important predictor of both the primary and
econdary composite outcomes (Table 2).
uartiles of baseline LDL-C. The LDL-C quartiles at
aseline (on average 7 days after admission) and after 4 months
f lipid-lowering treatment with pravastatin 40 mg and ator-
astatin 80 mg are shown in Figure 1. Median baseline
DL-C ranged from 81 mg/dl in the lowest quartile to 148
g/dl in the highest. Statin therapy reduced baseline LDL-C
n all quartiles except in the lowest, in which patients treated
ith pravastatin 40 mg had similar median LDL-C values
efore and after treatment (from 81 to 82 mg/dl). Absolute
eduction in LDL-C from baseline to month 4 values in-
reased progressively and significantly from lowest to highest
aseline LDL-C quartiles, regardless of the statin used (Fig. 2).
or patients treated with atorvastatin 80 mg, a median 26-
g/dl (34%) decrease in LDL-C level was achieved in the
owest quartile, whereas an 80-mg/dl (54%) decrease in
Quartiles of Baseline LDL-C
1
9)
Quartile 2
(n  785)
Quartile 3
(n  716)
Quartile 4
(n  736) p Value
102 121 148
93–112 112–132 132
57 56 54 0.001
78.9 79.1 76.6 0.67
91.2 91.2 90.2 0.55
85.9 86.2 86.2 0.92
45.6 42.5 37.1 0.001
29.1 31.8 42.8 0.001
38.0 42.7 44.3 0.002
16.2 15.8 10.6 0.001
4.0 3.8 3.8 0.99
9.6 10.3 8.7 0.21
6.6 7.8 7.9 0.56
5.5 6.0 4.1 0.11
1.9 1.8 2.5 0.82
8.3 9.3 7.0 0.09
39.6 38.0 38.0 0.19
5.5 5.0 4.6 0.82
24.0 22.5 21.9 0.42
1.40 1.52 1.22 0.004
95.0 93.6 95.1 0.48
88.7 83.2 84.7 0.02
13.9 17.3 14.0 0.03
60.8 57.8 53.5 0.003
54.7 42.2 32.9 0.001
74.1 69.7 72.6 0.26
ic, except where otherwise indicated. *Race was self-reported. †Killip class II was defined as the
lass IV as cardiogenic shock.C
uartile
 74
81
92
59
78.4
89.3
85.0
47.8
26.8
35.9
17.5
3.7
11.9
8.5
6.9
1.9
10.6
42.9
4.5
25.2
1.50
94.0
86.8
18.4
62.2
59.3
73.2
acterist
, and cass graft; LDL-C  low-density lipoprotein cholesterol; PCI  percutaneous coronary intervention;
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September 9, 2008:914–20 Baseline LDL-C and Benefit of Lipid LoweringDL-C was achieved in the highest quartile. Despite greater
bsolute and relative reductions of LDL-C in patients with
igher baseline levels, a stepwise increase in the achieved
DL-C at 4 months was seen from the lowest to the highest
uartile of baseline LDL-C regardless of treatment (p 0.001
or both agents) (Fig. 1). A significant increase from 30 to 40
g/dl (p  0.001) in the median absolute difference between
chieved LDL-C with pravastatin 40 mg and atorvastatin 80
g at 4 months was present from lowest to highest quartiles of
aseline LDL-C (Fig. 2).
rimary and secondary end points stratified by baseline
DL-C. In the highest baseline LDL-C quartile (132
g/dl), the primary end point at 2 years occurred in 29.8%
f patients allocated to pravastatin 40 mg, compared with
0.7% in the atorvastatin 80 mg group (HR: 0.63, 95% CI:
Figure 1 LDL-C at Baseline and After 4 Months of
Therapy Stratified by Quartiles of Baseline LDL-C
In the statin-naïve patients enrolled in the PROVE IT–TIMI 22 trial, baseline
LDL-C ranged from a median 81 mg/dl in the lowest quartile to 148 mg/dl in
the highest quartile. Lipid-lowering therapy decreased LDL-C in all quartiles
except for patients in the lowest quartile treated with pravastatin 40 mg. A
lower LDL-C level at 4 months was achieved with atorvastatin 80 mg compared
with pravastatin 40 mg in each quartile regardless of baseline values. A step-
wise increase in LDL-C achieved at 4 months was observed from the lowest to
the highest quartile of baseline LDL-C in patients randomized to both pravasta-
tin 40 mg and atorvastatin 80 mg (ptrend  0.001 for both). LDL-C  low-den-
sity lipoprotein cholesterol; Q  quartile.
redictors of the Primary and Secondary Outcomes
Table 2 Predictors of the Primary and Secondary Outcomes
Primary End Point
Independent Variable HR (95% CI) Z Score p Value
History of diabetes 1.36 (1.10–1.69) 2.85 0.004
Age* 1.12 (1.03–1.21) 2.61 0.009
Therapy with atorvastatin 0.82 (0.69–0.96) 2.47 0.01
C-reactive protein† 1.03 (1.01–1.05) 2.46 0.01
History of PCI 1.44 (1.08–1.94) 2.45 0.01
ultivariable models were also adjusted for variables significantly associated with the outcome
yocardial infarction, heart failure, peripheral vascular disease, renal disease, and CABG; type of
nd ACE/ARB inhibitors; baseline levels of cholesterol and triglycerides; and quartiles of baseline
f the outcomes. *HR for age represents increments of 10 years. †HR for C-reactive protein repre
CI   confidence interval; HR   hazard ratio; other abbreviations as in Table 1..47 to 0.85, p  0.002) (Fig. 3). A stepwise decline in the
enefit of atorvastatin 80 mg over pravastatin 40 mg was
een from highest to lowest baseline LDL-C quartile (Fig.
, Table 3). In the lowest quartile (baseline LDL-C 92
g/dl), the primary end point occurred in 23.8% of those
eceiving pravastatin 40 mg and 21.9% of those treated with
torvastatin 80 mg (HR: 0.93, 95% CI: 0.69 to 1.25, p 
.63). An interaction test between treatment group and
owest versus highest baseline LDL-C quartile adjusted for
ifferences in baseline characteristics was significant for the
omposite primary end point (p  0.03) (Table 3).
When baseline LDL-C was analyzed as a continuous
ariable, the benefit of atorvastatin 80 mg over pravastatin
0 mg was observed at baseline LDL-C values above
pproximately 66 mg/dl (Fig. 4) in a multivariate model
djusted for predictors of the primary end point (adjusted
nteraction p  0.02).
Intensive lipid-lowering therapy with atorvastatin 80 mg
s compared with pravastatin 40 mg also reduced the 2-year
Figure 2 Median Absolute Difference in LDL-C From Baseline
to 4 Months Stratified by Quartiles of Baseline LDL-C
A progressive increase in the difference from baseline to 4-month LDL-C values
was seen across quartiles of baseline LDL-C (ptrend  0.001 for both treat-
ments). The absolute median difference in LDL-C between patients randomized
to pravastatin 40 mg and atorvastatin 80 mg also increased as quartiles of
baseline LDL-C increased (p  0.001). Abbreviations as in Figure 1.
Secondary End Point
Independent Variable HR (95% CI) Z Score p Value
History of dyslipidemia 1.35 (1.12–1.63) 3.20 0.001
History of diabetes 1.43 (1.14–1.80) 3.10 0.002
C-reactive protein† 1.04 (1.01–1.06) 2.75 0.006
History of PCI 1.51 (1.10–2.08) 2.53 0.01
Therapy with atorvastatin 0.81 (0.68–0.97) 2.36 0.02
est in the univariate analysis, including history of hypertension, hypercholesterolemia, smoking,
oronary syndrome at admission; previous use of aspirin, beta-blockers, calcium-channel blockers,
n the multivariate analysis, these variables were not statistically significant (p  0.05) predictors
ncrements of 1 mg/dl.of inter
acute c
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Baseline LDL-C and Benefit of Lipid Lowering September 9, 2008:914–20vent rates of the secondary end point of CHD death, MI,
nd revascularization in the quartile of patients with the
ighest baseline LDL-C (HR: 0.57, 95% CI: 0.42 to 0.79,
 0.001) (Fig. 5), but not in patients within the lowest
aseline LDL-C quartile (HR: 0.98, 95% CI: 0.71 to 1.35,
 0.89). An adjusted interaction test between treatment
roup and lowest versus highest baseline LDL-C quartile
as significant for the secondary end point (p 0.007) (Fig.
, Table 3). The relationship between baseline LDL-C as a
ontinuous variable and the secondary end point also sug-
ested the emergence of a benefit in favor of atorvastatin 80
g compared to pravastatin 40 mg for baseline LDL-C
66 mg/dl (multivariate-adjusted interaction p  0.006).
iscussion
ur major finding is that the baseline LDL-C is an
mportant predictor of the benefit of intensive compared
Figure 3 HR for the Primary End Point
at 2 Years Stratified by Quartiles of Baseline LDL-C
A decrease in the benefit of atorvastatin 80 mg over pravastatin 40 mg was
seen from the highest to the lowest quartiles of baseline LDL-C. Treatment
with atorvastatin 80 mg reduced the primary end point compared with pravasta-
tin 40 mg in patients in the highest baseline LDL-C quartile, whereas similar
outcomes were observed in the lowest quartile of baseline LDL-C. An adjusted
interaction term between treatment assigned and quartile 1 versus 4 was sig-
nificant (p  0.03) for the primary end point. A  atorvastatin; HR  hazard
ratio; P  pravastatin; other abbreviations as in Figure 1.
rimary and Secondary End Points at 2 Years by Quartiles of Media
Table 3 Primary and Secondary End Points at 2 Years by Quart
Primary End Point*
Baseline LDL-C
Quartiles (Median) HR (95% CI) p Value‡
Unadjusted
Interaction§
1 (81 mg/dl) 0.93 (0.69–1.25) 0.63 0.07
2 (102 mg/dl) 0.84 (0.62–1.14) 0.26 0.19
3 (121 mg/dl) 0.85 (0.63–1.17) 0.32 0.16
4 (148 mg/dl) 0.63 (0.47–0.85) 0.002 Reference
esults are adjusted for the variables significantly related to the outcome of interest in the univar
equiring hospitalization, revascularization after 30 days, or stroke. †Secondary end point  coron
torvastatin 80 mg and pravastatin 40 mg in each quartile of baseline LDL-C. §Interaction p value betwe
Abbreviations as in Tables 1 and 2.ith moderate lipid-lowering therapy administered for 2
ears in high-risk statin-naïve patients admitted with an
CS. Although a significant reduction in the primary end
oint of all-cause mortality, MI, unstable angina requiring
ospitalization, revascularization performed after 30 days of
andomization, and stroke was observed in patients within
he highest quartile of baseline LDL-C (median LDL-C
48 mg/dl) randomized to atorvastatin 80 mg compared
ith pravastatin 40 mg, outcomes were similar between the
treatments in patients within the lowest quartile of
aseline LDL-C (median LDL-C 81 mg/dl). A test of
nteraction between statin therapy and lowest versus highest
uartile of baseline LDL-C was significant both for the
rimary and secondary end points, indicating that the
agnitude of clinical benefit of atorvastatin 80 mg over
ravastatin 40 mg observed in patients with elevated
DL-C at baseline was greater than that for patients in the
owest quartile of baseline LDL-C. Our results showed a
ecline in the superiority of atorvastatin 80 mg over prava-
tatin 40 mg from the highest to the lowest baseline LDL-C
uartile. When LDL-C was analyzed as a continuous
seline LDL-C
f Median Baseline LDL-C
Secondary End Point†
sted
tion§ HR (95% CI) p Value‡
Unadjusted
Interaction§
Adjusted
Interaction§
3 0.98 (0.71–1.35) 0.89 0.02 0.007
6 0.88 (0.63–1.22) 0.44 0.07 0.02
8 0.85 (0.61–1.19) 0.35 0.09 0.05
ence 0.57 (0.42–0.79) 0.001 Reference Reference
lysis (see Methods section). *Primary end point  death, myocardial infarction, unstable angina
rt disease death, myocardial infarction, or revascularization after 30 days. ‡Comparison between
Figure 4 Logit of the Primary End Point
Stratified by Continuous Baseline LDL-C
When LDL-C was treated as a continuous variable, the benefit of atorvastatin
80 mg over pravastatin 40 mg for the prevention of the primary end point was
not present at baseline levels of LDL-C 66 mg/dl. A significant multivariate-
adjusted interaction between treatment and baseline LDL-C was observed
(adjusted interaction p  0.02). Abbreviations as in Figure 1.n Ba
iles o
Adju
Interac
0.0
0.0
0.0
Refer
iate ana
ary heaen treatment assignment and baseline LDL-C quartiles.
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September 9, 2008:914–20 Baseline LDL-C and Benefit of Lipid Loweringariable, the benefit of intensive lipid-lowering therapy was
ot seen in patients with baseline LDL-C 66 mg/dl.
The reasons for the reduced benefit of intensive statin
herapy in patients with lower baseline LDL-C are not fully
nderstood. Because of the apparent log-linear relationship
etween LDL-C levels and cardiovascular events, a greater
enefit of intensive cholesterol reduction would be expected
n patients with elevated baseline LDL-C (5). However, it
s also possible that the greater reduction in LDL-C
bserved with atorvastatin 80 mg in patients with higher
aseline values might have partially contributed to this
ifference in benefit. The absolute difference in LDL-C
chieved at 4 months with pravastatin 40 mg versus ator-
astatin 80 mg significantly increased by one-third from the
owest to the highest quartile. Disparity in baseline charac-
eristics and hospital treatment among quartiles of baseline
DL-C might have accounted for some of the differences
een in the benefit of intensive therapy as well, despite
ultivariable adjustments. Patients with lower baseline
DL-C were older and had greater comorbidities, such as
iabetes and hypertension, that may have played a more
mportant role in the risk of future events than LDL-C. The
enefit of lipid therapy in these groups of patients is still under
crutiny (13,14) although it seems to be a safe strategy (15,16).
Previous studies in patients with acute and chronic CHD
ave evaluated the role of baseline LDL-C on the benefit of
ipid-lowering therapy. Although the LIPID (Long-Term
ntervention with Pravastatin in Ischaemic Disease) (8) and
ARE (Cholesterol And Recurrent Events) (7) trials showed
lower threshold for the benefit of statin therapy with
ravastatin 40 mg, investigators from the 4S study (Scandina-
ian Simvastatin Survival Study) (9) found a similar benefit of
Figure 5 HR for the Secondary End Point
at 2 Years in Quartiles of Baseline LDL-C
A progressive decrease in the benefit of atorvastatin 80 mg over pravastatin
40 mg with respect to the secondary end point was seen from the highest to
the lowest baseline LDL-C quartile. Significant adjusted interactions for the out-
come were seen between therapy and quartiles 1 and 4 (p  0.007), 2 and 4
(p  0.02), and 3 and 4 (p  0.05). Abbreviations as in Figures 1 and 3.imvastatin over placebo irrespective of baseline LDL-C. vikewise, the Heart Protection Study did not detect a lower
oundary for the benefit of simvastatin over placebo (11). Key
ifferences exist between our analysis and earlier placebo-
ontrolled studies that randomized patients with chronic cor-
nary disease and with much higher baseline LDL-C levels at
time when potent lipid-lowering agents were not available.
ecause of the relatively low mean LDL-C of 112 mg/dl in the
tatin-naïve population at baseline and highly reduced LDL-C
evels achieved with atorvastatin 80 mg in the PROVE
T–TIMI 22 trial, these data provided a unique opportunity to
valuate the impact of baseline LDL-C on the effect of 2 statin
egimens of differing LDL-lowering intensities on clinical
utcomes in the modern era.
Recent evidence has shown that aggressive reduction of
DL-C to lower levels might be beneficial for the prevention
f cardiovascular events (2,3,16–18). However, the optimal
arget LDL-C remains unknown, and large randomized trials
re underway to investigate the benefit of reaching even lower
alues of LDL-C (19). The markedly reduced LDL-C levels
chieved with atorvastatin 80 mg compared with pravastatin 40
g in each quartile of baseline LDL-C allowed for the
omparison of the impact of progressively lower LDL-C on
ardiovascular outcomes. In the lowest quartile of baseline
DL-C, cardiovascular events were similar in patients treated
ith atorvastatin 80 mg and pravastatin 40 mg, although the
DL-C levels achieved after 4 months of therapy were 53
g/dl and 82 mg/dl, respectively. As achieved LDL-C in-
reased across increasing quartiles of baseline LDL-C, the
enefit of more intensive therapy became evident. In the
ighest quartile, patients with a median LDL-C of 72 mg/dl
fter 4 months of therapy with atorvastatin 80 mg had
mproved outcomes compared with those who achieved a
edian LDL-C of 112 mg/dl after 4 months of pravastatin 40
g. Therefore, it is possible that reduction of LDL-C to very
ow levels (60 mg/dl) in patients with reduced baseline levels
efore therapy might not be effective in post-ACS patients
ollowed up for 2 years. Our data suggest that most of the
verall reduction in cardiovascular events seen for 2 years with
ntensive lipid lowering in PROVE IT–TIMI 22 was derived
rom patients with higher baseline LDL-C.
The finding that aggressive lipid treatment might not be
equired in patients with reduced baseline LDL-C has important
linical implications. The use of moderately intensive regimens in
cohort of patients with reduced baseline LDL-C may result in
ewer side effects, reduced drug costs, and higher adherence to
herapy (20,21).
tudy limitations. The PROVE IT–TIMI 22 trial was not
esigned with sufficient power to detect differences in
reatment effect within quartiles of baseline LDL-C, as was
erformed in our post hoc analysis. However, a consistent
tepwise reduction in the benefit of intensive lipid-lowering
herapy was identified from highest to lowest quartile of
aseline LDL-C. Additionally, interaction tests showed a
ifference in the benefit of atorvastatin 80 mg over prava-
tatin 40 mg in patients with baseline LDL-C 132 mg/dl
ersus 92 mg/dl. One important confounding factor in
t
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atients stratified by baseline LDL-C. However, multivar-
ate models that included adjustment for differences in
aseline characteristics, baseline C-reactive protein, and an
nteraction term between therapy and quartiles of baseline
DL-C confirmed a difference in the relative benefit of the
regimens of varying LDL-C–lowering intensity. Finally,
ecause the effect of statin therapy was less intense in
atients with low baseline LDL-C, it is possible that if even
ore potent lipid-lowering agents or longer follow-up were
sed, clinical benefit for the patients in this subgroup might
ave been observed. This exploratory analysis should be
nterpreted as hypothesis generating, and needs to be
ollowed by definitive, prospective studies that could ulti-
ately refine recommendations regarding patients with
CS who are most likely to benefit from intensive lipid-
owering therapy. Similarly, the lower threshold of baseline
DL-C of 66 mg/dl observed for the benefit of intensive
tatin therapy should not be extrapolated for use in clinical
ractice without further prospective validation.
onclusions
n this analysis, we showed that in patients after an ACS,
aseline LDL-C is an important predictor of the benefit of
ntensive lipid-lowering therapy compared with therapy of
oderate intensity. Over an average follow-up period of 2
ears, statin-naïve patients with baseline LDL-C 66
g/dl did not seem to benefit from a reduction in LDL-C
ith atorvastatin 80 mg compared with pravastatin 40 mg.
his observation suggests that intensive statin therapy may
ot be necessary in patients whose baseline LDL-C is
lready low. Indirectly, our data suggest that there may be
n actual target LDL-C to reach by lipid-lowering therapies
f different intensities. However, further studies will be
ecessary to address this question. In the interim, our
nalyses support the current guideline recommendations to
onsider initiation of statin therapy in high-risk patients
ith ACS if the LDL-C is above 100 mg/dl, and to target
n LDL-C ideally 70 mg/dl (22).
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